PCN74 Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC)

Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.166
https://www.valueinhealthjournal.com/article/S1098-3015(21)00383-1/fulltext
Title : PCN74 Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00383-1&doi=10.1016/j.jval.2021.04.166
First page :
Section Title :
Open access? : No
Section Order : 10748
Categories :
Tags :
Regions :
ViH Article Tags :